UCB announced an additional upgrade to its 2025 financial guidance. Revenue is expected to exceed 7.6 billion euros, up 24% year-on-year. Excluding non-recurringimpact, 2025 adjusted EBITDA margin is anticipated to be higher than 31%. UCB will publish the 2025 results and formal financial guidance for 2026 on February 26,2026. UCB noted that its 2025 guidance further reinforces confidence in the company's decade-plus growth ambition.
The company said its upgraded guidance reflects - next to the continued growth of RYSTIGGO, ZILBRYSQ, FINTEPLA and EVENITY - the exceptional performance of BIMZELX, including a strong momentum in hidradenitis suppurativa and a favorable payer mix in the U.S.
For comments and feedback contact: editorial@rttnews.com
Business News
May 15, 2026 15:25 ET Apart from the confirmation of Kevin Warsh as the next Fed chair, the main news on the economics front this week included key price data from the U.S. and the first quarter economic growth figures from major economies. Both consumer prices and producer costs have started to reflect the effect of supply shocks due to the Middle East conflict. In Europe, GDP data was in focus, while inflation data from China dominated the news flow in Asia.